Compare CYRX & CION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYRX | CION |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.3M | 464.0M |
| IPO Year | 2008 | 2011 |
| Metric | CYRX | CION |
|---|---|---|
| Price | $7.93 | $6.81 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 9 | 1 |
| Target Price | ★ $12.94 | $7.00 |
| AVG Volume (30 Days) | 425.4K | ★ 738.5K |
| Earning Date | 03-03-2026 | 03-12-2026 |
| Dividend Yield | N/A | ★ 17.17% |
| EPS Growth | ★ 156.22 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $176,177,000.00 | N/A |
| Revenue This Year | $10.92 | N/A |
| Revenue Next Year | $8.08 | N/A |
| P/E Ratio | ★ $5.86 | $17.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.63 | $6.50 |
| 52 Week High | $11.45 | $10.93 |
| Indicator | CYRX | CION |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 31.14 |
| Support Level | $6.57 | $6.50 |
| Resistance Level | $8.52 | $10.30 |
| Average True Range (ATR) | 0.39 | 0.24 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 29.44 | 25.00 |
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.